<DOC>
	<DOC>NCT01683695</DOC>
	<brief_summary>This is a multicenter, randomized, double-blind, parallel, placebo-controlled, multiple dose study that will enroll approximately 40 systemic lupus erythematosus subjects with active lupus arthritis.</brief_summary>
	<brief_title>Safety Study of AMG 557 in Subjects With Lupus Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Lupus Erythematosus, Systemic</mesh_term>
	<criteria>Diagnosis of SLE for at least 6 months as defined by the most recent American College of Rheumatology criteria Presence of lupus related inflammatory arthritis with at least four tender and four swollen joints; and Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) â‰¥ 6 at screening; Other inclusion criteria may apply. Presence or history of vasculitis, and presence or history of active lupus nephritis requiring therapy within the last 3 years Any disorder (including psychiatric), condition, clinically significant disease, disease activity related to SLE Positive for HIV antibodies, hepatitis B surface antigen or antiHBc, or hepatitis C antibodies Known residential exposure to an individual with tuberculosis or positive Quantiferon test or PPD test at screening Men and women of reproductive potential, unwilling to practice a highly effective method of birth control for the duration of the study Other exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Lupus Arthritis, Systemic Lupus Erythematosus, AMG 557, Lupus</keyword>
</DOC>